
    
      To determinate and to describe the clonal evolution, 30 DLBCL cases with available matched
      tumor DNA and plasma will be collected and analyzed by routinely applicable next generation
      sequencing (NGS) at the time of diagnosis, at mid treatment, at the end of treatment and at
      12 months after diagnosis.
    
  